Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy
Introduction: Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors. Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-e...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2025-04-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/4976 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849314622470881280 |
|---|---|
| author | Annunziata Dattola Nicoletta Bernardini Elena Campione Emanuele Amore Simone Amato Giacomo Caldarola Clara De Simone Domenico Giordano Gaia Moretta Vincenzo Panasiti Gianluca Pagnanelli Vincenzo Roberti Ruslana Gaeta Shumak Nevena Skroza Ersilia Tolino Paola Tribuzi Salvatore Zanframundo Luca Bianchi Severino Persechino Concetta Potenza Giovanni Pellacani Ketty Peris Antonio Giovanni Richetta |
| author_facet | Annunziata Dattola Nicoletta Bernardini Elena Campione Emanuele Amore Simone Amato Giacomo Caldarola Clara De Simone Domenico Giordano Gaia Moretta Vincenzo Panasiti Gianluca Pagnanelli Vincenzo Roberti Ruslana Gaeta Shumak Nevena Skroza Ersilia Tolino Paola Tribuzi Salvatore Zanframundo Luca Bianchi Severino Persechino Concetta Potenza Giovanni Pellacani Ketty Peris Antonio Giovanni Richetta |
| author_sort | Annunziata Dattola |
| collection | DOAJ |
| description |
Introduction: Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors.
Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-experienced patients with moderate-to-severe psoriasis over a 52-week period, with a focus on improvements across different body areas and QoL.
Methods: A retrospective analysis of real-world data was conducted on 132 patients from 8 medical centers. Efficacy was assessed using PASI scores, at baseline and at weeks 4, 16, 24, and 52, and DLQI scores. Patients were categorized based on prior biologic treatment experience.
Results: The mean PASI score decreased for all patients, from 14.41 at baseline to 0.18 at week 52, indicating substantial improvement. Area-specific PASI subscores showed significant reductions: head (3.24 to 0.13), upper limb (8.49 to 0), trunk (8.35 to 0.03), and lower limb (8.61 to 0.12). Complete skin clearence was achieved by week 16 in the majority of patients: 85% achieved complete skin clearance in the head, 90% in upper limbs, and 94% in both trunk and lower limbs. DLQI scores significantly improved from 13.57 at baseline to 0.86 at week 16, highlighting the early positive impact of bimekizumab in improving QoL. When comparing PASI scores between bio-naive and bio-experienced patients, no significant difference was found.
Conclusions: Bimekizumab demonstrates significant efficacy in reducing psoriasis severity across different body areas and improving QoL over a 52-week period. These findings support this robust treatment option for moderate-to-severe psoriasis.
|
| format | Article |
| id | doaj-art-57bdff8ac8ee48139f00cffcc34002b2 |
| institution | Kabale University |
| issn | 2160-9381 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Dermatology Practical & Conceptual |
| spelling | doaj-art-57bdff8ac8ee48139f00cffcc34002b22025-08-20T03:52:24ZengMattioli1885Dermatology Practical & Conceptual2160-93812025-04-0115210.5826/dpc.1502a4976Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, ItalyAnnunziata Dattola0Nicoletta Bernardini 1Elena Campione 2Emanuele Amore 3Simone Amato 4Giacomo Caldarola 5Clara De Simone 6Domenico Giordano 7Gaia Moretta 8Vincenzo Panasiti 9Gianluca Pagnanelli 10Vincenzo Roberti 11Ruslana Gaeta Shumak12Nevena Skroza13Ersilia Tolino 14Paola Tribuzi15Salvatore Zanframundo 16Luca Bianchi 17Severino Persechino 18Concetta Potenza 19Giovanni Pellacani 20Ketty Peris 21Antonio Giovanni Richetta 22Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.Dermatology Unit, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, ItalyDepartment of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma.Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, ItalyDepartment of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma.Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italyruslanagaetashumak@gmail.comDermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyDermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyUOSD Ospedale Belcolle ASL Viterbo, ItalyDepartment of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, ItalyDermatology Unit, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, ItalyDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, ItalyDermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy Introduction: Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors. Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-experienced patients with moderate-to-severe psoriasis over a 52-week period, with a focus on improvements across different body areas and QoL. Methods: A retrospective analysis of real-world data was conducted on 132 patients from 8 medical centers. Efficacy was assessed using PASI scores, at baseline and at weeks 4, 16, 24, and 52, and DLQI scores. Patients were categorized based on prior biologic treatment experience. Results: The mean PASI score decreased for all patients, from 14.41 at baseline to 0.18 at week 52, indicating substantial improvement. Area-specific PASI subscores showed significant reductions: head (3.24 to 0.13), upper limb (8.49 to 0), trunk (8.35 to 0.03), and lower limb (8.61 to 0.12). Complete skin clearence was achieved by week 16 in the majority of patients: 85% achieved complete skin clearance in the head, 90% in upper limbs, and 94% in both trunk and lower limbs. DLQI scores significantly improved from 13.57 at baseline to 0.86 at week 16, highlighting the early positive impact of bimekizumab in improving QoL. When comparing PASI scores between bio-naive and bio-experienced patients, no significant difference was found. Conclusions: Bimekizumab demonstrates significant efficacy in reducing psoriasis severity across different body areas and improving QoL over a 52-week period. These findings support this robust treatment option for moderate-to-severe psoriasis. https://dpcj.org/index.php/dpc/article/view/4976Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis |
| spellingShingle | Annunziata Dattola Nicoletta Bernardini Elena Campione Emanuele Amore Simone Amato Giacomo Caldarola Clara De Simone Domenico Giordano Gaia Moretta Vincenzo Panasiti Gianluca Pagnanelli Vincenzo Roberti Ruslana Gaeta Shumak Nevena Skroza Ersilia Tolino Paola Tribuzi Salvatore Zanframundo Luca Bianchi Severino Persechino Concetta Potenza Giovanni Pellacani Ketty Peris Antonio Giovanni Richetta Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy Dermatology Practical & Conceptual Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis |
| title | Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy |
| title_full | Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy |
| title_fullStr | Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy |
| title_full_unstemmed | Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy |
| title_short | Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy |
| title_sort | evaluating the efficacy of bimekizumab across different sensitive areas in moderate to severe psoriasis 52 week multicentric real life experience in lazio italy |
| topic | Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis |
| url | https://dpcj.org/index.php/dpc/article/view/4976 |
| work_keys_str_mv | AT annunziatadattola evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT nicolettabernardini evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT elenacampione evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT emanueleamore evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT simoneamato evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT giacomocaldarola evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT claradesimone evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT domenicogiordano evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT gaiamoretta evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT vincenzopanasiti evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT gianlucapagnanelli evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT vincenzoroberti evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT ruslanagaetashumak evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT nevenaskroza evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT ersiliatolino evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT paolatribuzi evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT salvatorezanframundo evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT lucabianchi evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT severinopersechino evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT concettapotenza evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT giovannipellacani evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT kettyperis evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly AT antoniogiovannirichetta evaluatingtheefficacyofbimekizumabacrossdifferentsensitiveareasinmoderatetoseverepsoriasis52weekmulticentricreallifeexperienceinlazioitaly |